
National and Regional HIV/STI Perspectives (

Melanie Taylor MD, MPH Centers for Disease Control and Prevention National STD Program, Indian Health Service May 2012




Overview

- Epidemiology Updates
- STD Testing/Treatment Updates
- Provider and Site Performance Measures
- IHS/CDC Standard Protocols for STD Care (
 - Sexual Risk Assessment
 - Policy
 - Protocol
 - Patient Delivered partner Therapy
 - STD Screening Recommendations




Survival After an AIDS Diagnosis




^b Hispanics/Latinos can be of any race.



Chlamydia by Race, (2009 CDC, STD Surveillance, 2009 (




Chlamydia Rates by County, 2009 CDC, STD Surveillance, 2009 (




Source: Centers for Disease Control and Prevention, Sexually Transmitted Disease Surveillance, 2008. Atlanta, GA: U.S. Department of Health and Human

Chlamydia Rates among Al/AN by IHS Area, 2009 (



Chlamydia by Gender, Age, 2009 CDC, STD Surveillance, 2009 (



Gonorrhea

- Dramatic increases in gonorrhea cases among AI/AN populations during 2010-2012
 - Alaska
 - Arizona
 - New Mexico
 - North Dakota
 - South Dakota

Centers for Disease Control and Prevention



Gonorrhea Treatment Uncomplicated Genital/Rectal Infections

Ceftriaxone 250 mg IM in a single dose

OR, if not an option:

PLUS*

Azithromycin 1 g orally or Doxycycline 100 mg BID x 7 days

Cefixime 400 mg orally in a single dose

* Regardless of CT test result

CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment Gonorrhea Treatment (Oropharyngeal Infections

> Ceftriaxone 250 mg IM in a single dose

PLUS

Azithromycin 1 g orally or Doxycycline 100 mg BID x 7 days

IN CASE OF SEVERE ALLERGY:

Azithromycin 2 g orally once



STD Treatment Updates

Gonorrhea treatment rationale:

- 1. Isolates demonstrating decreased susceptibility to cephalosporins
- 2. Reports of ceftriaxone treatment failures.
- 3. Improved efficacy of ceftriaxone 250mg in pharyngeal infections.
- 4. Consistent dosing regardless of infection site.



STD Screening Updates

- 1. Annual gonorrhea and chlamydia screening in sexually active women age 25 and under.
- 2. Screening women <35 years that are in adult detention facilities for chlamydia and gonorrhea
- 3. Patients presenting for an STD evaluation should be offered HSV-2 (genital herpes) serologic testing
- 4. Pregnant women: screening for asymptomatic (1) bacterial vaginosis (2) genital herpes [HSV-2 serology]
 (3)trichomoniasis is NOT recommended

Chlamydia/Gonorrhea Screening

- Self-collected vaginal swabs preferred specimen in females;
- Urine preferred in males







First Void vs. Clean Catch Urine

- Annals of Family Medicine. 2012;10 (1); 50-53.
- 100 women with first void urine positive for chlamydia also provided a mid-stream sample (
- 96 (96%) had a positive mid-stream specimen
- Suggests a suitable sensitivity for testing mid-stream urines
- Opportunities for batching CT/GC testing with urine pregnancy testing

STD Testing Updates (

- Rectal and pharyngeal site testing in men who have sex with men (MSM) for chlamydia and gonorrhea using Nucleic Acid Amplification Tests (NAAT)
 - 1. Requires lab validation (facilitated by CDC)
 - 2. Both SonoraQuest and LabCorps have capacity to perform
- Retesting persons diagnosed with chlamydia and gonorrhea 3 months following initial diagnosis (7-24% re-infection rate)



Ordering Codes (

Ordering Codes for Combined GC/CT NAAT			Ordering Codes for CT-only NAAT
	LabCorps	Quest	LabCorps
Rectal	188672	16506	188706
Pharyngeal	188698	7005 I	188714
Current Procedural Terminology Billing Codes			
CT detection by NAAT	87491		
GC detection by NAAT	87591		

Syphilis



- <u>Diagnosis</u>: Reverse serology screening challenges
- <u>Treatment</u>: No extra dose of BIC for primary, secondary, and early latent syphilis in HIVinfected patients
- <u>CSF evaluation</u>: only for neuro symptoms, tertiary syphilis, or serologic treatment failure





Diagnosis of Syphilis (



- Serology
 - Non-treponemal (non-specific, cardiolipin-based)
 - RPR or VDRL
 - Treponemal (specific to Treponema pallidum)
 - TP-PA, FTA-abs, EIA, CIA
- Darkfield microscopy
- Polymerase Chain Reaction



Why switch to EIA/CLIA for Syphilis Screening? (

- Automated
- Low cost in high volume settings
- Less lab occupational hazard (pipetting)
- More objective results
- No false negatives due to prozone reaction


180 tests per hour, no manual pipetting



Discordant Syphilis Results

- MMWR, 2011;60 (5):133-137
- Syphilis EIA testing
- I40, I76 specimens screened
 - 4,834 (3.4%) reactive
 - 2,743 (56.7%) non-reactive by RPR
 - 866 (32%) non reactive by TP-PA or FTA-ABS
- Findings: Low prevalence populations with high false-positive results







EXPEDITED PARTNER Therapy IN ARIZONA


Chlamydia and Gonorrhea

YOU CAN TREAT THE PARTNERS

Expedited Partner Therapy (EPT)

- Also referred to as "Patient Delivered Partner Therapy"
- Practiced according to state law
- Chlamydia or Gonorrhea patient delivers an extra dose of medication or a prescription to sex partner(s).
 - Gonorrhea
 - Cefixime 400mg x I dose PLUS azithromycin I gm x I
 - Chlamydia
 - Azithromycin I gm PO x I

Expedited Partner Therapy (EPT)



EPT is permissible in 27 states:

EPT is potentially allowable in 15 states:

EPT is prohibited in 8 states:

EPT and IHS (

- Ideal settings
 - Women's clinic
 - Primary care medical clinics
- Opportunities
 - Pharmacy EHR option for EPT
 - Azithromycin 2 grams, one gram each for patient and partner
 - Follow-up of empirically treated cases
 - Urgent care
 - ED

Indian Health Service: (Monitoring Clinical Practice (



4 National IHS Measures (

- I. (Prenatal HIV Screening (GPRA)
- 2. (HIV Screening of 13-64 y.o.
- 3. (Chlamydia screening of sexually active 15-24 y.o. females annually
- 4. (HIV screen for patients newly diagnosed with STD (

ALL 4 MEASURES BASED ON NATIONAL GUIDELINES AND RECOMMENDATIONS

Screening Rationale (

- Long term manifestations of untreated chlamydia/gonorrhea
 - Pelvic inflammatory disease (PID)
 - Infertility
 - Ectopic pregnancy
 - Chronic pelvic pain
 - Epididymitis


IHS STI Screening Rates

- Prenatal HIV Screening 86%
- HIV Screening of 13-64 y.o. 8.7%
- Chlamydia screening of sexually active 15-24 y.o. females annually 26%
- HIV screen for patients newly diagnosed with STD 31%


Effective Deployment of a Clinical Reminder at a Clinic of the IHS to Increase HIV Screening among Adolescents and Adults

- Clinic developed and deployed clinical reminder in July 2010
- Reminder identified eligible clients between the ages of 13-64 not screened for HIV in the past 5 years
- 500% increase in screening the six following reminder deployment

Template 4 Reminders Due Due EPSDT Evaluation ✓ Order HIV screening test Applicabl Not Applicable All Evaluated Other Categorie Indicates a Required Field CLINICAL REMINDER ACTIVITY HIV Screening Due: Order HIV screening test Diagnoses: SPECIAL SCREENING EXAMINATION, OTHER SPECIFIED VIBAL DISEASES Patient Educations: HIV-TESTS Clinical Maint < Back Finish Cancel Clear



Use of EHR reminder/dialogue: CT tests, IHS clinic, June 2011-May 2012



CT tests, IHS clinic, June 2011-May 2012

Increase of 137%

 Improved targeting of testing/screening: percentage of CT positive tests <u>increased</u>

STI Screening Opportunities (

- Reproductive Health Services (
 - Prenatal
 - Family Planning
 - Well woman exams
 - HPV vaccinations
- Routine Laboratory Testing
 - Urine based pregnancy testing
 - Urinalysis
 - Urine culture

New IHS/CDC Policy (

- Purpose: To expand opportunities for confidential STD/HIV screening and treatment among AI/AN populations
- Rationale:
 - Compliance with national standards and IHS (performance measures (
 - High STD rates among AI/AN populations
 - Differences in time to treatment
 - Limited partner treatment in some areas (
 - Late HIV diagnoses



IHS/CDC Protocol

- Clear step by step guidance:
 - STD/HIV screening in pregnancy
 - HIV screening in general populations
 - STD screening in women and special populations
 - STD treatment
 - Partner management
 - Presumptive treatment of partners
 - Patient delivered partner therapy (PDPT)
 - Vaccination (HPV, HBV) (



IHS/CDC Guidance

- Supplements:
 - IHS STD/HIV screening recommendations (chart)
 - Performing a sexual risk assessment
 - Patient delivered partner therapy
 - Patient information sheet (chlamydia & gonorrhea)
 - Partner information sheet (chlamydia)
 - Partner information sheet (gonorrhea) (




IHS/CDC Protocols

- Intended for use and/or adaptation by: (
 - IHS Service Units
 - Remote or village-level clinics
 - Regional IHS medical centers
 - Tribal corporation medical facilities (
 - 638 facilities



Summary

- Epidemiology:
 - High STD rates among AI/AN populations;
 - Poor HIV/AIDS survival
- 4 National Performance Measures
- New STD Treatment Guidelines
- IHS/CDC STD Care Protocols



FOR MORE INFORMATION, PLEASE CONTACT:

MDT7@CDC.GOV (